Fenwick Represents Attovia Therapeutics in $90M Series C Funding

Fenwick represented Attovia Therapeutics, a clinical-stage biopharma company developing treatments for immune-mediated diseases, in its $90 million Series C funding. The round was led by Deep Track Capital with participation from Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science.

Attovia Therapeutics will use the funds to advance its lead assets, ATTO-1310 and ATTO-3712, through clinical proof-of-concept, with the aim of achieving best-in-disease efficacy for the treatment of chronic pruritus and atopic dermatitis. More information can be obtained from the company announcement.

The Fenwick transaction team was led by corporate partner Matt Rossiter and included associates Kristen Nicol and Lindsey Macalalad.